Serine protease
Serine protease | |||||||||
---|---|---|---|---|---|---|---|---|---|
![]() Crystal structure of bovine chymotrypsin. The catalytic residues are shown as yellow sticks. Rendered from PDB 1CBW. | |||||||||
Identifiers | |||||||||
EC no. | 3.4.21.- | ||||||||
Databases | |||||||||
IntEnz | IntEnz view | ||||||||
BRENDA | BRENDA entry | ||||||||
ExPASy | NiceZyme view | ||||||||
KEGG | KEGG entry | ||||||||
MetaCyc | metabolic pathway | ||||||||
PRIAM | profile | ||||||||
PDB structures | RCSB PDB PDBe PDBsum | ||||||||
|
![](http://upload.wikimedia.org/wikipedia/commons/thumb/d/d5/1UTN.png/250px-1UTN.png)
Serine proteases (or serine endopeptidases) are enzymes that cleave peptide bonds in proteins. Serine serves as the nucleophilic amino acid at the (enzyme's) active site.[1] They are found ubiquitously in both eukaryotes and prokaryotes. Serine proteases fall into two broad categories based on their structure: chymotrypsin-like (trypsin-like) or subtilisin-like.[2]
Classification
The MEROPS protease classification system counts 16 superfamilies (as of 2013) each containing many families. Each superfamily uses the catalytic triad or dyad in a different protein fold and so represent convergent evolution of the catalytic mechanism. The majority belong to the S1 family of the PA clan (superfamily) of proteases.
For superfamilies, P: superfamily, containing a mixture of nucleophile class families, S: purely serine proteases. superfamily. Within each superfamily, families are designated by their catalytic nucleophile, (S: serine proteases).
![](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/2PTN.gif/220px-2PTN.gif)
Super- family | Families | Examples |
---|---|---|
SB | S8, S53 | Subtilisin (Bacillus licheniformis) |
SC | S9, S10, S15, S28, S33, S37 | Prolyl oligopeptidase (Sus scrofa) |
SE | S11, S12, S13 | D-Ala-D-Ala peptidase C (Escherichia coli) |
SF | S24, S26 | Signal peptidase I (Escherichia coli) |
SH | S21, S73, S77, S78, S80 | Cytomegalovirus assemblin (human herpesvirus 5) |
SJ | S16, S50, S69 | Lon-A peptidase (Escherichia coli) |
SK | S14, S41, S49 | Clp protease (Escherichia coli) |
SO | S74 | Phage K1F endosialidase CIMCD self-cleaving protein (Enterobacteria phage K1F) |
SP | S59 | Nucleoporin 145 (Homo sapiens) |
SR | S60 | Lactoferrin (Homo sapiens) |
SS | S66 | Murein tetrapeptidase LD-carboxypeptidase (Pseudomonas aeruginosa) |
ST | S54 | Rhomboid-1 (Drosophila melanogaster) |
PA | S1, S3, S6, S7, S29, S30, S31, S32, S39, S46, S55, S64, S65, S75 | Chymotrypsin A (Bos taurus) |
PB | S45, S63 | Penicillin G acylase precursor (Escherichia coli) |
PC | S51 | Dipeptidase E (Escherichia coli) |
PE | P1 | DmpA aminopeptidase (Brucella anthropi) |
None | S48, S62, S68, S71, S72, S79, S81 |
Substrate specificity
Serine proteases are characterised by a distinctive structure, consisting of two beta-barrel domains that converge at the catalytic active site. These enzymes can be further categorised based on their substrate specificity as either trypsin-like, chymotrypsin-like or elastase-like.[5]
Trypsin-like
Trypsin-like proteases cleave peptide bonds following a positively charged amino acid (lysine or arginine).[6] This specificity is driven by the residue which lies at the base of the enzyme's S1 pocket (generally a negatively charged aspartic acid or glutamic acid).
Chymotrypsin-like
The S1 pocket of chymotrypsin-like enzymes is more hydrophobic than in trypsin-like proteases. This results in a specificity for medium to large sized hydrophobic residues, such as tyrosine, phenylalanine and tryptophan.
Thrombin-like
These include thrombin, tissue activating plasminogen and plasmin. They have been found to have roles in coagulation and digestion as well as in the pathophysiology of neurodegenerative disorders such as Alzheimer's and Parkinson's induced dementia. Many highly-toxic thrombin-like serine protease isoforms are found in snake venoms.[7]
Elastase-like
Elastase-like proteases have a much smaller S1 cleft than either trypsin- or chymotrypsin-like proteases. Consequently, residues such as alanine, glycine and valine tend to be preferred.
Subtilisin-like
Subtilisin is a serine protease in prokaryotes. Subtilisin is evolutionarily unrelated to the chymotrypsin-clan, but shares the same catalytic mechanism utilising a catalytic triad, to create a nucleophilic serine. This is the classic example used to illustrate convergent evolution, since the same mechanism evolved twice independently during evolution.
Catalytic mechanism
![serine protease reaction mechanism](http://upload.wikimedia.org/wikipedia/commons/thumb/1/17/Serine_protease_mechanism_by_snellios.png/400px-Serine_protease_mechanism_by_snellios.png)
The main player in the catalytic mechanism in the serine proteases is the catalytic triad. The triad is located in the active site of the enzyme, where catalysis occurs, and is preserved in all superfamilies of serine protease enzymes. The triad is a coordinated structure consisting of three amino acids: His 57, Ser 195 (hence the name "serine protease") and Asp 102. These three key amino acids each play an essential role in the cleaving ability of the proteases. While the amino acid members of the triad are located far from one another on the sequence of the protein, due to folding, they will be very close to one another in the heart of the enzyme. The particular geometry of the triad members are highly characteristic to their specific function: it was shown that the position of just four points of the triad characterize the function of the containing enzyme.[8]
In the event of catalysis, an ordered mechanism occurs in which several intermediates are generated. The catalysis of the peptide cleavage can be seen as a ping-pong catalysis, in which a substrate binds (in this case, the polypeptide being cleaved), a product is released (the C-terminus "half" of the peptide with amino group visible), another substrate binds (in this case, water), and another product is released (the N-terminus "half" of the peptide with carboxyl group visible).
Each amino acid in the triad performs a specific task in this process:
- The serine has an -OH group that is able to act as a nucleophile, attacking the carbonyl carbon of the scissile peptide bond of the substrate.
- A pair of electrons on the histidine nitrogen has the ability to accept the hydrogen from the serine -OH group, thus coordinating the attack of the peptide bond.
- The carboxyl group on the aspartic acid in turn hydrogen bonds with the histidine, making the nitrogen atom mentioned above much more electronegative.
The whole reaction can be summarized as follows:
- The polypeptide substrate binds to the surface of the serine protease enzyme such that the scissile bond is inserted into the active site of the enzyme, with the carbonyl carbon of this bond positioned near the nucleophilic serine.
- The serine -OH attacks the carbonyl carbon, and the nitrogen of the histidine accepts the hydrogen from the -OH of the [serine] and a pair of electrons from the double bond of the carbonyl oxygen moves to the oxygen. As a result, a tetrahedral intermediate is generated.
- The bond joining the nitrogen and the carbon in the peptide bond is now broken. The covalent electrons creating this bond move to attack the hydrogen of the histidine, breaking the connection. The electrons that previously moved from the carbonyl oxygen double bond move back from the negative oxygen to recreate the bond, generating an acyl-enzyme intermediate.
- Now, water comes into the reaction. Water replaces the N-terminus of the cleaved peptide, and attacks the carbonyl carbon. Once again, the electrons from the double bond move to the oxygen making it negative, as the bond between the oxygen of the water and the carbon is formed. This is coordinated by the nitrogen of the histidine, which accepts a proton from the water. Overall, this generates another tetrahedral intermediate.
- In a final reaction, the bond formed in the first step between the serine and the carbonyl carbon moves to attack the hydrogen that the histidine just acquired. The now electron-deficient carbonyl carbon re-forms the double bond with the oxygen. As a result, the C-terminus of the peptide is now ejected.
Additional stabilizing effects
It was discovered that additional amino acids of the protease, Gly 193 and Ser 195, are involved in creating what is called an oxyanion hole. Both Gly 193 and Ser 195 can donate backbone hydrogens for hydrogen bonding. When the tetrahedral intermediate of step 1 and step 3 are generated, the negative oxygen ion, having accepted the electrons from the carbonyl double bond, fits perfectly into the oxyanion hole. In effect, serine proteases preferentially bind the transition state and the overall structure is favored, lowering the activation energy of the reaction. This "preferential binding" is responsible for much of the catalytic efficiency of the enzyme.
Regulation of serine protease activity
Host organisms must ensure that the activity of serine proteases is adequately regulated. This is achieved by a requirement for initial protease activation, and the secretion of inhibitors.
Zymogen activation
Zymogens are the usually inactive precursors of an enzyme. If the digestive enzymes were active when synthesized, they would immediately start chewing up the synthesizing organs and tissues. Acute pancreatitis is such a condition, in which there is premature activation of the digestive enzymes in the pancreas, resulting in self-digestion (autolysis). It also complicates postmortem investigations, as the pancreas often digests itself before it can be assessed visually.
Zymogens are large, inactive structures, which have the ability to break apart or change into the smaller activated enzymes. The difference between zymogens and the activated enzymes lies in the fact that the active site for catalysis of the zymogens is distorted. As a result, the substrate polypeptide cannot bind effectively, and proteolysis does not occur. Only after activation, during which the conformation and structure of the zymogen change and the active site is opened, can proteolysis occur.
Zymogen | Enzyme | Notes |
---|---|---|
Trypsinogen | trypsin | When trypsinogen enters the small intestine from the pancreas, enteropeptidase secretions from the duodenal mucosa cleave the lysine 15 - isoleucine 16 peptide bond of the zymogen. As a result, the zymogen trypsinogen breaks down into trypsin. Recall that trypsin is also responsible for cleaving lysine peptide bonds, and thus, once a small amount of trypsin is generated, it participates in cleavage of its own zymogen, generating even more trypsin. The process of trypsin activation can thus be called autocatalytic. |
Chymotrypsinogen | chymotrypsin | After the Arg 15 - Ile 16 bond in the chymotrypsinogen zymogen is cleaved by trypsin, the newly generated structure called a pi-chymotrypsin undergoes autolysis (self digestion), yielding active chymotrypsin. |
Proelastase | elastase | It is activated by cleavage through trypsin. |
As can be seen, trypsinogen activation to trypsin is essential, because it activates its own reaction, as well as the reaction of both chymotrypsin and elastase. Therefore, it is essential that this activation does not occur prematurely. There are several protective measures taken by the organism to prevent self-digestion:
- The activation of trypsinogen by trypsin is relatively slow
- The zymogens are stored in zymogen granules, capsules that have walls that are thought to be resistant to proteolysis.
Inhibition
There are certain inhibitors that resemble the tetrahedral intermediate, and thus fill up the active site, preventing the enzyme from working properly. Trypsin, a powerful digestive enzyme, is generated in the pancreas. Inhibitors prevent self-digestion of the pancreas itself.
Serine proteases are paired with serine protease inhibitors, which turn off their activity when they are no longer needed.[9][self-published source?]
Serine proteases are inhibited by a diverse group of inhibitors, including synthetic chemical inhibitors for research or therapeutic purposes, and also natural proteinaceous inhibitors. One family of natural inhibitors called "serpins" (abbreviated from serine protease inhibitors) can form a covalent bond with the serine protease, inhibiting its function. The best-studied serpins are antithrombin and alpha 1-antitrypsin, studied for their role in coagulation/thrombosis and emphysema/A1AT, respectively. Artificial irreversible small molecule inhibitors include AEBSF and PMSF.
A family of arthropod serine peptidase inhibitors, called pacifastin, has been identified in locusts and crayfish, and may function in the arthropod immune system.[10]
Role in disease
Mutations may lead to decreased or increased activity of enzymes. This may have different consequences, depending on the normal function of the serine protease. For example, mutations in protein C can lead to protein C deficiency and predisposing to thrombosis. Also, some proteases play a vital role in host cell-virus fusion activation by priming virus's Spike protein to show the protein named "fusion protein" (TMPRSS2 activate SARS-CoV-2 fusion). Exogenous snake venom serine proteases cause a vast array of coagulopathies when injected in a host due to the lack of regulation of their activity.[7]
Diagnostic use
Determination of serine protease levels may be useful in the context of particular diseases.
- Coagulation factor levels may be required in the diagnosis of hemorrhagic or thrombotic conditions.
- Fecal elastase is employed to determine the exocrine activity of the pancreas, e.g., in cystic fibrosis or chronic pancreatitis.
- Serum prostate-specific antigen is used in prostate cancer screening, risk stratification, and post-treatment monitoring.
- Serine protease, as released by mast cells, is an important diagnostic marker for type 1 hypersensitivity reactions e.g., anaphylaxis. More useful than histamine due to the longer half-life, meaning it remains in the system for a clinically useful length of time.
Antimicrobial effect
Due to their catalytic activity, some serine proteases possess potent antimicrobial properties. Several in vitro studies have demonstrated the efficacy of some proteases in reducing virulence by cleaving viral surface proteins. Viral entry into host cells is mediated by the interaction of these surface proteins with the host cell. When these proteins are fragmented or inactivated on the viral surface, the viral entry is impaired, leading to a reduction in infectivity of a broad spectrum of pathologically relevant microorganisms like Influenza, hRSV and others.[11][12]
See also
- Serine hydrolase
- Protease
- PA clan
- Convergent evolution
- Proteolysis
- Catalytic triad
- The Proteolysis Map
- Proteases in angiogenesis
- Intramembrane proteases
- Protease inhibitor (pharmacology)
- Protease inhibitor (biology)
- TopFIND - database of protease specificity, substrates, products and inhibitors
- MEROPS - Database of protease evolutionary groups
- Keratinase
- Subtilisin
- Proteinase K
References
- ^ Hedstrom L (December 2002). "Serine protease mechanism and specificity". Chemical Reviews. 102 (12): 4501–4524. doi:10.1021/cr000033x. PMID 12475199.
- ^ Madala PK, Tyndall JD, Nall T, Fairlie DP (June 2010). "Update 1 of: Proteases universally recognize beta strands in their active sites". Chemical Reviews. 110 (6): PR1–P31. doi:10.1021/cr900368a. PMID 20377171.
- ^ Khade PM, Kumar A, Jernigan RL (January 2020). "Characterizing and Predicting Protein Hinges for Mechanistic Insight". Journal of Molecular Biology. 432 (2): 508–522. doi:10.1016/j.jmb.2019.11.018. PMC 7029793. PMID 31786268.
- ^ Khade PM, Scaramozzino D, Kumar A, Lacidogna G, Carpinteri A, Jernigan RL (November 2021). "hdANM: a new comprehensive dynamics model for protein hinges". Biophysical Journal. 120 (22): 4955–4965. Bibcode:2021BpJ...120.4955K. doi:10.1016/j.bpj.2021.10.017. PMC 8633836. PMID 34687719.
- ^ Ovaere P, Lippens S, Vandenabeele P, Declercq W (September 2009). "The emerging roles of serine protease cascades in the epidermis". Trends in Biochemical Sciences. 34 (9): 453–463. doi:10.1016/j.tibs.2009.08.001. PMID 19726197.
- ^ Evnin LB, Vásquez JR, Craik CS (September 1990). "Substrate specificity of trypsin investigated by using a genetic selection". Proceedings of the National Academy of Sciences of the United States of America. 87 (17): 6659–6663. Bibcode:1990PNAS...87.6659E. doi:10.1073/pnas.87.17.6659. JSTOR 2355359. PMC 54596. PMID 2204062.
- ^ a b Oliveira AL, Viegas MF, da Silva SL, Soares AM, Ramos MJ, Fernandes PA (2022-06-10). "The chemistry of snake venom and its medicinal potential". Nature Reviews. Chemistry. 6 (7): 451–469. doi:10.1038/s41570-022-00393-7. PMC 9185726. PMID 35702592.
- ^ Iván G, Szabadka Z, Ordög R, Grolmusz V, Náray-Szabó G (June 2009). "Four spatial points that define enzyme families". Biochemical and Biophysical Research Communications. 383 (4): 417–420. CiteSeerX 10.1.1.150.1086. doi:10.1016/j.bbrc.2009.04.022. PMID 19364497.
- ^ "Kimball's Biology Pages, Serine Proteases". Archived from the original on 2005-12-13. Retrieved 2008-06-02.
- ^ Breugelmans B, Simonet G, van Hoef V, Van Soest S, Vanden Broeck J (March 2009). "Pacifastin-related peptides: structural and functional characteristics of a family of serine peptidase inhibitors". Peptides. 30 (3): 622–632. doi:10.1016/j.peptides.2008.07.026. PMID 18775459. S2CID 8797134.
- ^ Lopes BR, da Silva GS, de Lima Menezes G, de Oliveira J, Watanabe AS, Porto BN, et al. (May 2022). "Serine proteases in neutrophil extracellular traps exhibit anti-Respiratory Syncytial Virus activity". International Immunopharmacology. 106: 108573. doi:10.1016/j.intimp.2022.108573. PMID 35183035.
- ^ Sakai K, Ami Y, Tahara M, Kubota T, Anraku M, Abe M, et al. (May 2014). Dermody TS (ed.). "The host protease TMPRSS2 plays a major role in in vivo replication of emerging H7N9 and seasonal influenza viruses". Journal of Virology. 88 (10): 5608–5616. doi:10.1128/JVI.03677-13. PMC 4019123. PMID 24600012.
External links
- The MEROPS online database for peptidases and their inhibitors: Serine Peptidase Archived 2017-04-04 at the Wayback Machine
- Serine Proteases site at Saint Louis University (SLU)
- Serine+proteases at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- v
- t
- e
3.4.11 | |
---|---|
3.4.13 | |
3.4.14 | |
3.4.15 | |
3.4.16 | |
3.4.17 | |
Other/ungrouped |